医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Geneious Desktop Software to Be Renamed to Geneious Prime

2018年08月28日 PM10:00
このエントリーをはてなブックマークに追加


 

AUCKLAND, New Zealand

Biomatters today announces that Geneious, its world-leading desktop suite of molecular biology and sequence analysis tools, will be renamed to Geneious Prime later this year.

Geneious began as a way to reduce time spent on managing and analyzing biological data and is now widely used in biotechnology and academic research. Over half a million scientists have used Geneious in the 13 years since its first release. In the last two years Geneious has doubled the size of its customer base in commercial biotech and pharma, particularly driven by customers working in biologic drug development.

President and CEO Brett Ammundsen commented “Over the last decade our customers have associated Geneious with trust, expertise and approachability. As we continue to grow and adapt to the market, that same Geneious experience has to encompass a wider range of solutions for customers who have been with us for years, as well as new customers. The time has come to give our desktop software its own identity.”

Director of Marketing, Melissa Pentecost says “Prime connotes being the best in class and the first choice for researchers and lab managers who are seeking a solution to their sequence data analysis and data management challenges. It also references its status as the original solution that we brought to market.”

About Geneious Prime

Geneious Prime increases efficiency and enables better science as the world’s most recognized and comprehensive desktop suite of molecular biology and NGS analysis tools. First released in 2005, Geneious Prime is used by over 4,000 universities, institutes and commercial companies in 125 countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180828005033/en/

CONTACT

Further information contact
Biomatters Limited
Melissa
Pentecost, +21 258 1005
melissa@geneious.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
  • MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil
  • SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • 首例神经母细胞瘤患者成功接受采用自然杀伤T细胞(CAR-NKT)的创新型CAR疗法